Biogen says mid-stage optic nerve treatment study succeeds

January 8, 2015 1:11 PM

17 0

(Reuters) - Biogen Idec Inc said on Thursday a mid-stage study of a new treatment for acute optic neuritis, an inflammation of the optic nerve that can lead to complete or partial loss of vision, showed evidence of biological repair of the visual system.

Biogen shares rose 6 percent to $375 in premarket trading from a close of $353.24.

Read more

To category page